Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

119140 Adenosine Receptor Agonist, NECA - CAS 35920-39-9 - Calbiochem

119140
Purchase on Sigma-Aldrich

Overview

Replacement Information

Products

Catalogue NumberPackaging Qty/Pack
119140-10MG Glass bottle 10 mg
Description
OverviewA cell-permeable adenosine analog that acts a potent non-selective agonist of adenosine receptors (Ki = 14 nM, 20 nM, 2.4 µM and 6.2 nM for A1, A2A, A2B, A3, respectively). Increases intracellular cAMP production (EC50 = 3.1 µM in A2B expressing CHO cells). Shown to increase glucagon release in a dose-dependent manner and inhibit insulin release at low concentrations. Although at higher concentration some insulin release is observed. Also, displays a wide range adenosine-dependent effects, such as blocking platelet aggregation and inhibiting DNA synthesis. When administered at reperfusion, it is shown reduce infarction and block the formation of the mitochondrial permeability transition pore by activating p70S6 kinase.
Catalogue Number119140
Brand Family Calbiochem®
Synonyms(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-N-ethyl-3,4-dihydroxytetrahydrofuran-2-carboxamide
References
ReferencesForster, K., et al. 2006. Basic Res. Cardiol. 101, 319.
de Zwart, M., et al. 1998. Nucleosides Nucleotides. 17, 969.
Phillis, J. et al. 1986, Pharm. Biochem. Behavior.24, 263
Durcan, M. J., et al. 1989. Pharmacol Biochem Behav. 32, 487.
Bacher, S., et al. 1982. Naunyn Schmiedebergs Arch Pharmacol. 329, 67.
Cusack, N., et al. 1981. Br J Pharm.72, 443.
Londos, C., et al. 1980. Proc Natl Acad Sci.77, 2551.
Product Information
CAS number35920-39-9
FormWhite solid
Hill FormulaC₁₂H₁₆N₆O₄
Chemical formulaC₁₂H₁₆N₆O₄
ReversibleY
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Primary Target K<sub>i</sub>14 nM
Purity≥98% by HPLC
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
Toxicity Standard Handling
Storage +2°C to +8°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications

Documentation

Adenosine Receptor Agonist, NECA - CAS 35920-39-9 - Calbiochem SDS

Title

Safety Data Sheet (SDS) 

Adenosine Receptor Agonist, NECA - CAS 35920-39-9 - Calbiochem Certificates of Analysis

TitleLot Number
119140

References

Reference overview
Forster, K., et al. 2006. Basic Res. Cardiol. 101, 319.
de Zwart, M., et al. 1998. Nucleosides Nucleotides. 17, 969.
Phillis, J. et al. 1986, Pharm. Biochem. Behavior.24, 263
Durcan, M. J., et al. 1989. Pharmacol Biochem Behav. 32, 487.
Bacher, S., et al. 1982. Naunyn Schmiedebergs Arch Pharmacol. 329, 67.
Cusack, N., et al. 1981. Br J Pharm.72, 443.
Londos, C., et al. 1980. Proc Natl Acad Sci.77, 2551.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision25-September-2019 JSW
Synonyms(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-N-ethyl-3,4-dihydroxytetrahydrofuran-2-carboxamide
DescriptionA cell-permeable adenosine analog that acts a potent non-selective agonist of adenosine receptors (Ki = 14 nM, 20 nM, 2.4 µM and 6.2 nM for A1, A2A, A2B, A3, respectively). Increases intracellular cAMP production (EC50 = 3.1 µM in A2B expressing CHO cells). Shown to increase glucagon release in a dose-dependent manner and inhibit insulin release at low concentrations. Although at higher concentration some insulin release is observed. Also, displays a wide range adenosine-dependent effects, such as blocking platelet aggregation and inhibiting DNA synthesis. When administered at reperfusion, it is shown reduce infarction and block the formation of the mitochondrial permeability transition pore by activating p70S6 kinase.
FormWhite solid
Intert gas (Yes/No) Packaged under inert gas
CAS number35920-39-9
Chemical formulaC₁₂H₁₆N₆O₄
Structure formulaStructure formula
Purity≥98% by HPLC
SolubilityDMSO (50 mM)
Storage +2°C to +8°C
Protect from light
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity Standard Handling
ReferencesForster, K., et al. 2006. Basic Res. Cardiol. 101, 319.
de Zwart, M., et al. 1998. Nucleosides Nucleotides. 17, 969.
Phillis, J. et al. 1986, Pharm. Biochem. Behavior.24, 263
Durcan, M. J., et al. 1989. Pharmacol Biochem Behav. 32, 487.
Bacher, S., et al. 1982. Naunyn Schmiedebergs Arch Pharmacol. 329, 67.
Cusack, N., et al. 1981. Br J Pharm.72, 443.
Londos, C., et al. 1980. Proc Natl Acad Sci.77, 2551.